Cognition Therapeutics announces positive results from trial of oral treatment for mild-to-moderate Alzheimer's disease
Cognition Therapeutics Inc. on Monday announced positive results from a Phase 2 trial of an oral treatment for mild-to-moderate Alzheimer's disease that showed 40% mean improvement in cognitive measures compared with placebo.The Purchase, N.Y.-based company said the trial, called Shine, found patients treated with its experimental pill CT1812 for six months showed a consistent trend in cognitive improvement across all measures and cognitive scales."The SHINE trial showed that after 182 days of treatment, CT1812 demonstrated evidence of clinical improvements on cognition coupled with a favorable safety and tolerability profile, particularly in the 100mg dose cohort," Chief Executive Lisa Ricciardi said in prepared remarks."We believe these results provide evidence that amyloid oligomer antagonism - a new and distinct mechanism for therapeutic intervention - may have a role as a monotherapy or in a combination with approved drugs for the treatment of AD and related dementias.". The resu